Opinion|Videos|July 29, 2024
Ongoing Research in Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
An expert on hidradenitis suppurativa gives an overview of the current research landscape, highlighting exciting developments in the treatment space.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What are the other investigational agents for hidradenitis suppurativa (HS) that you are excited about and what is their stage in development?
Advertisement
Related to this article
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Melatonin Use Linked to Small REM Sleep Reduction in Children
5